Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
PHENYLEPHRINE HYDROCHLORIDE (UNII: 04JA59TNSJ) (PHENYLEPHRINE - UNII:1WS297W6MV)
Meitheal Pharmaceuticals Inc.
INTRAVENOUS
PRESCRIPTION DRUG
Phenylephrine Hydrochloride Injection is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. None Risk Summary Data from randomized controlled trials and meta-analyses with phenylephrine hydrochloride injection use in pregnant women during Cesarean section have not established a drug-associated risk of major birth defects and miscarriage. These studies have not identified an adverse effect on maternal outcomes or infant Apgar scores [see Data] . There are no data on the use of phenylephrine hydrochloride during the first or second trimester. In animal reproduction and development studies in normotensive animals, evidence of fetal malformations was noted when phenylephrine hydrochloride was administered during organogenesis via a 1-hour infusion at 1.2 times the human daily dose (HDD) of 10 mg/60 kg/day. Decreased pup weights were noted in offspring of pregnant rats treated with 2.9 times the HDD [See Data]. The estimated backgrou
Phenylephrine Hydrochloride Injection, USP, 10 mg per mL, is a clear, colorless solution supplied as follows: Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F). [see USP Controlled Room Temperature]. Protect from light. Store in carton until time of use. The diluted solution should not be held for more than 4 hours at room temperature or for more than 24 hours under refrigerated conditions. Discard any unused portion. Sterile, Nonpyrogenic. The container closure is not made with natural rubber latex.
Abbreviated New Drug Application
PHENYLEPHRINE HYDROCHLORIDE- PHENYLEPHRINE HYDROCHLORIDE INJECTION MEITHEAL PHARMACEUTICALS INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE PHENYLEPHRINE HYDROCHLORIDE INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR PHENYLEPHRINE HYDROCHLORIDE INJECTION. PHENYLEPHRINE HYDROCHLORIDE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1954 INDICATIONS AND USAGE Phenylephrine Hydrochloride Injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. (1) DOSAGE AND ADMINISTRATION Phenylephrine hydrochloride injection, 10 mg per mL, is injected intravenously either as a bolus or in a dilute solution as a continuous infusion. Dilute before administration. (2) Dosing for treatment of hypotension during anesthesia Bolus intravenous injection: 40 mcg to 100 mcg every 1-2 minutes as needed, not to exceed 200 mcg. (2) Intravenous infusion: 10 mcg/min to 35 mcg/min, titrating to effect, not to exceed 200 mcg/min. (2) Adjust the dose according to the pressor response (i.e., titrate to effect). (2) DOSAGE FORMS AND STRENGTHS Injection (3) 5 mL pharmacy bulk package vials containing 50 mg phenylephrine hydrochloride (10 mg per mL) (3) 10 mL pharmacy bulk package vials containing 100 mg phenylephrine hydrochloride (10 mg per mL) (3) CONTRAINDICATIONS None (4) WARNINGS AND PRECAUTIONS Exacerbation of Angina, Heart Failure, or Pulmonary Arterial Hypertension: Phenylephrine hydrochloride can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure. (5.1) Peripheral and Visceral Ischemia: Phenylephrine hydrochloride can cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs. (5.2) Skin and Subcutaneous Necrosis: Extravasation during intravenous administration may cause necrosis or slou Lue koko asiakirja